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Genomic instability plays a crucial role in oncogenesis. Somatically acquired mutations can disable some genes and inappropriately
activate others. In addition, chromosomal rearrangements can amplify, delete, or even fuse genes, altering their functions and
contributing to malignant phenotypes. Using array comparative genomic hybridization (aCGH), a technique to detect numeric
variations between different DNA samples, we examined genomes from zebrafish (Danio rerio) T-cell leukemias of three cancer-
prone lines. In all malignancies tested, we identified recurring amplifications of a zebrafish endogenous retrovirus. This retrovirus,
ZFERV, was first identified due to high expression of proviral transcripts in thymic tissue from larval and adult fish. We confirmed
ZFERV amplifications by quantitative PCR analyses of DNA from wild-type fish tissue and normal and malignant D. rerio T
cells. We also quantified ZFERV RNA expression and found that normal and neoplastic T cells both produce retrovirally encoded
transcripts, but most cancers show dramatically increased transcription. In aggregate, these data imply that ZFERV amplification
and transcription may be related to T-cell leukemogenesis. Based on these data and ZFERV’s phylogenetic relation to viruses of the
murine-leukemia-related virus class of gammaretroviridae, we posit that ZFERV may be oncogenic via an insertional mutagenesis
mechanism.
1. Introduction
Zebrafish are an emerging animal model for the study of
lymphocytic cancers. A landmark 2003 study first described
that transgenic murine Myc (mMyc) misexpression could
induce D. rerio T-cell acute lymphoblastic leukemia (T-ALL)
[1]. Since that initial report, several other zebrafish ALL
models have been described, utilizing transgenic mammalian
TEL-AML1 (human), NOTCH1 (human), MYC (murine
and human), and AKT2 (murine) in similar fashion [2–5].
In addition, we used a phenotypic mutagenesis screen to
create three further zebrafish models with heritable T-ALL
predisposition [6]. All but one of the eight lines cited above
are prone to T-ALL, not B-cell-lineage cancers. Like human
T-ALL, D. rerio T-ALL often arises in or spreads to the
thymus and forms tumors. Hence, these seven zebrafish
lines actually more accurately model two related lymphocyte
malignancies, T-ALL and T-cell lymphoblastic lymphoma
(T-LBL). In fact, mMyc zebrafish have even been used
to investigate the molecular changes that accompany the
transition between T-LBL and T-ALL [7].
Because the molecular origins of T-ALL and T-LBL are
not completely understood, these zebrafish models provide
opportunities to investigate the genetic underpinnings of
these diseases’ oncogenesis. In addition, they also facilitate
inquiries designed to reveal features associated with T-ALL
and T-LBL progression. For example, in the aforementioned
study, Feng et al. demonstrated that changes in BCL2, S1P1,
and ICAM1 expression were linked to autophagy, intercellu-
lar adhesion, and intravascular invasion, thereby governing
the T-LBL to T-ALL transition [7]. Similarly, Gutierrez et al.
used transgenic zebrafish T-ALL to study the dependence of
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MYC-driven cancers upon Pten and Akt for disease persist-
ence and progression [5].
While these two studies utilized D. rerio models to
investigate candidate genes of suspected importance to
disease progression, zebrafish T-cell cancers can also serve
as a means for candidate gene discovery. In our own work,
we utilized serial allo-transplantation of D. rerio T-ALL
as an experimental approach to model clinically aggressive
neoplasia [8]. Similar strategies have been employed by other
groups, using serially allo-grafted murine T-cell lymphomas
or xeno-transplanted human T-ALL into immunodeficient
mice [9, 10]. In our study, we performed aCGH to seek
acquired genomic changes common to serially passaged
D. rerio T-ALL and refractory/relapsed human T-ALL.
Several candidate genes met this criterion, including C7orf60
(zebrafish homologue, zgc: 153606), a gene whose amplifica-
tions were linked to both accelerated T-ALL progression in
fish and inferior outcomes in human T-ALL patients [8].
Although our study concentrated on acquired copy
number aberrations (CNAs) shared by zebrafish and human
T-ALL, we also identified other genomic amplifications and
deletions seen only in D. rerio cancers. Amongst these, two
recurring copy number gains were observed in every sample,
and with further scrutiny we found that both regions cor-
responded to the same endogenous retrovirus (ERV). This
genomically integrated provirus is predicted to have 2–4
integration sites in the zebrafish genome [11], and its
ploidy and genomic positions may vary between individual
animals, complicating its inquiry. In this paper, we use two
independent methodologies to show that this multicopy
ERV undergoes further amplification in both normal and
neoplastic zebrafish T cells, which could create new and
potentially oncogenic integrations. Some cancers showed
very high ZFERV copy number, well above that seen in
T lymphocytes. We also demonstrate the expression of
retrovirally encoded RNAs by both normal and cancerous D.
rerio T cells, with most malignancies displaying significantly
elevated proviral transcription relative to normal T cells.
Our findings, and further characterization of this ERV,
will be essential to understanding how this biologically
active retrovirus impacts normal and malignant zebrafish T
lymphocyte biology.
2. Materials and Methods
2.1. Zebrafish Lines and Care. Adult fish from five D. rerio
lines were analyzed: normal WIK strain lck::EGFP fish [12],
the ENU mutant lines hulk, shrek, and oscar the grouch
(hlk, srk, otg; all WIK background) [6], and rag2::MYC-
ER × lck::EGFP fish (nacre × WIK hybrid) [5]. Fish were
housed using standard conditions (28.5◦C, 14 hr. light/10 hr.
dark circadian cycle) in a colony at the University of Utah’s
zebrafish core facility. For examinations under fluorescent
microscopy, fish were anesthetized with 0.02% tricaine
methanesulfonate (MS222) and euthanized with ice water
prior to dissections. Animals were handled according to NIH
guidelines, under an approved protocol (IACUC #08-08005)
by the University of Utah Animal Care and Use Committee.
2.2. Dissections and Fluorescence-Activated Cell Sorting
(FACS). Zebrafish thymi and GFP+ tumors were dissected,
with preparation of single cell suspensions and FACS per-
formed as described previously [6]. BD FACSVantage and
FACSAria II SORP (Becton Dickson) instruments were used
for FACS. GFP intensity and side- and forward-scatter were
gating parameters for GFP+ lymphocyte collections.
2.3. Nucleic Acid Purifications. Genomic DNA for aCGH and
qPCR was extracted from FACS-purified GFP+ T cells and
matched tailfin tissue using the DNeasy Blood and Tissue
Kit (Qiagen) as described previously [8]. Total RNA for qRT-
PCR assays was extracted from FACS-purified T lymphocytes
and T cell cancers with Trizol (Invitrogen) or the RNeasy
Mini-Kit (Qiagen) according to manufacturer instructions.
RNA samples were treated with RNase-Free DNase (Qiagen)
according to manufacturer instructions prior to qRT-PCR.
2.4. Array Comparative Genomic Hybridization (aCGH).
Genomic DNA was labeled with the BioPrime Labeling Kit
(Invitrogen), purified, quantified, and hybridized to Zv6-
based Zebrafish Genomic Arrays (NimbleGen) as reported
previously [8]. Arrays were analyzed using the G2565CA
Microarray Scanner System with SureScan High Resolution
Technology (Agilent) and normalized using Agilent Feature
Extraction software. Copy-number analysis was conducted
using the Rank Segmentation algorithm with Nexus Copy
Number 5.0 software (BioDiscovery). Detailed descriptions
of the aCGH methods used and copy number analyses
performed are available in the supplemental sections of the
report by Rudner et al. [8].
2.5. Quantitative Polymerase Chain Reactions (qPCR). A
LightCycler CFX96 (Bio-Rad) was used for qPCR assays.
Briefly, IQ SYBR Green Supermix (Bio-Rad) was used to
amplify genomic DNA from various tissue types. Pooled
thymocyte DNA (our limiting sample) was spectrophoto-
metrically quantified and then diluted 1 : 100 for use in
qPCR. DNA from tailfin tissue and GFP+ tumor cells were
diluted to identical concentrations, with 2 μL of each DNA
used in reactions with total volumes of 25 μL, and other
components added according to manufacturer instructions.
All reactions were performed in triplicate. SYBR Green
signals were used to derive estimates of relative ZFERV copy
number. Since true ZFERV copy number is unknown, values
were arbitrarily normalized to 1 copy/haploid genome. Thus,
a ZFERV relative copy number equal to 3 indicates three
times as many ZFERV copies/genome (e.g., if germline copy
number = 3 copies/haploid genome, ZFERV relative copy
number = 3 indicates 9 copies/haploid genome). All qPCR
results with pol and env were normalized to elf2a, present
in 1 copy/D. rerio haploid genome. Primers and reaction
conditions were as follows:
Forward pol primer: CGC-CCC-ACA-CAT-CAC-
ATA
Reverse pol primer: CAA-CCA-TCA-CAG-AAC-
AGA
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Forward env primer: ATG-TTT-GGG-GAA-TGG-
AAG-G
Reverse env primer: TTT-GAT-AAG-GAG-GTG-
GGT-TTT
Forward elf2a primer: TGG-AGG-TGG-AGG-TGA-
GAA-CT
Reverse elf2a primer: GAG-TGG-TTG-TGT-AAG-
CAT-TTC-G
Denaturation: 95◦C × 3 minutes
40 cycles:
95◦C × 10 seconds
59◦C × 40 seconds
Melt curve analysis—55◦C–95◦C.
2.6. Quantitative Reverse Transcription Polymerase Chain
Reactions (qRT-PCR). Total RNA (200 ng/sample) from
FACS-purified normal and malignant T cells was assayed
with the iScript One-step RT-PCR Kit with SYBR Green
(Bio-Rad) using the aforementioned equipment. Reactions
were run in triplicate. Results with pol and env were normal-
ized to elf2a, assayed in parallel qRT-PCRs. Expression fold
changes were calculated by the 2−ΔΔCt method. Primers and
reaction conditions were as follows:
Forward pol primer: CAG-CAC-AAA-CGA-AAA-
TGG-TCT
Reverse pol primer: TGG-CTC-CTC-AGT-GTC-
TCC-TT
Forward env primer: AGA-GGG-AAA-GGA-TGG-
GAT-GT
Reverse env primer: TGT-TGG-ATG-TGG-TCT-
GGT-CT
Forward elf2a primer: ATG-AGA-CAA-TGG-GGA-
GAG-CA
Reverse elf2a primer: GGA-TGC-GGC-TGG-AGT-
TTC
Denaturation: 95◦C × 5 minutes
40 cycles:
95◦C × 10 seconds
52◦C × 10 seconds
72◦C × 30 seconds
Melt curve analysis—55◦C–95◦C.
2.7. Statistical Analyses. The student’s t-test was used to
compare differences in genomic relative copy number or fold
changes in RNA expression. P values < 0.05 were considered
significant.
3. Results and Discussion
We previously performed an ENU-mutagenesis phenotypic
screen designed to identify abnormal T-cell phenotypes.
Our screen resulted in the discovery of three D. rerio lines
(srk, hlk, otg) prone to T-cell malignancies, specifically T-
ALL and T-LBL [6]. To investigate non-germline acquired
genetic changes occurring in these cancers, we used aCGH
to compare DNA of neoplastic and normal tissues from
individual fish of each of these lines. These experiments
revealed several homologous genes that are commonly
amplified or deleted in both zebrafish and human T-ALL [8].
In those studies, >98% of D. rerio genes with somatically
acquired CNAs also had identifiable human counterparts.
However, two non-homologous genomic regions unique
to zebrafish were also particularly interesting. These loci
showed copy number gains in 8/8 zebrafish T-cell cancer
genomes relative to DNA of nonmalignant tissues from the
same animals (Figure 1). Notably, T-ALLs from all three
lines (3/3 srk, 3/3 hlk, 2/2 otg) exhibited copy number
gains in both regions, establishing these acquired genomic
amplifications as consistent features in T-cell cancers arising
from different genetic backgrounds. Our aCGH experiments
used a NimbleGen microarray platform constructed from the
Zv6 genomic assembly. We subsequently discovered that the
probes displaying amplified signals were mistakenly assigned
to distinct regions on chromosomes 7 and 14 (hybridization
data depicted in Figure 1). However, upon closer inspection
these probes actually derive from a single, approximately
11 kb, locus. Intriguingly, this region corresponds to a
genomically integrated retroviral element dubbed ZFERV by
Shen and Steiner, named as such because it is the first and
thus far only described zebrafish endogenous retrovirus [11].
In scrutinizing the six aCGH probe sequences localized
to these two chromosomes, we realized they were in fact
distributed throughout the ZFERV genome (Figure 2).
Collectively, our hybridization results with these 6 probes
provide compelling evidence that the entire ZFERV locus
is undergoing somatic amplifications in the genomes of
zebrafish T-cell cancers. Because our aCGH data is internally
normalized by comparing each cancer’s DNA to paired
non-malignant tailfin DNA from the same fish, our results
are protected from possible ZFERV copy number variation
(CNV) that might exist between different animals. However,
due to ambiguity regarding initial (i.e., germline) ZFERV
copy number in individual fish, it is impossible to deduce the
absolute number of copies gained by each cancer. Instead,
our findings are limited to the conclusion that ZFERV has
been amplified, relative to the original number of ZFERV
copies, in 8/8 T cell malignancies tested. Moreover, because
“normal” ZFERV copy number and genomic locations may
vary between fish or between strains, thus far, determining
absolute ZFERV copy number prior to oncogenesis has been
challenging.
Reinforcing the complexity of this issue, previous D. rerio
genome builds have displayed ZFERV in multiple locations
on each assembly, and also on several different linkage
groups (LG 1, 5, 7, 14, 15, 16, 17, and 22). It is inherently
difficult to accurately map multicopy loci like ZFERV, and
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Figure 1: Recurrent amplifications of a small genomic locus in zebrafish T-ALL. Ten kb loci on chromosomes 7 and 14 (Zv6 genomic
assembly) show high-copy gains with multiple probes in these regions (black arrows) of 8/8 D. rerio T-ALL samples tested. Signal intensities
above a “high-copy gain threshold” (upper green line) indicate a greater than 2-fold increase in copy number. Individual probes and their
intensities are depicted as blue dots; areas with 3 adjacent probes above the high-copy gain threshold use green dots to denote those probes.
Seven cancers exhibited high-copy signals for ≥5/6 probes in this region, while srk T-ALL3 had high-copy signals for only 2/6 probes.
this is made even more taxing by its sequence composi-
tion. ZFERV harbors several redundant sequence tracks,
including 5′ and 3′ long terminal repeats (LTRs) and a
517 bp repeat region (RR) containing 9 consecutive repeat
elements (see Figure 2). When compounded with potential
variability resulting from strain-specific ZFERV integrations,
it is perhaps predictable that ZFERV has not received
definitive chromosomal map position(s). Consequently, the
current NCBI zebrafish genome actually suppresses ZFERV
sequences and curates them so they do not appear on the
Zv9 assembly at all.
In the original report describing ZFERV, Shen and
Steiner conducted studies to address some of these questions
concerning copy number and genomic localization: to prove
that ZFERV was integrated into the D. rerio germline, they
tested sperm DNA from several Tübingen (Tü) fish and
verified an integration site common to each of their genomes
[11]. Additionally, using Southern blots of Tü genomic DNA,
they detected 2–4 bands hybridizing to a ZFERV env probe,
implying a maximum of four retroviral copies per haploid
genome [11]. However, not all Tü fish showed identical
hybridization patterns. This could be due to restriction site
polymorphisms in the Tü strain but might also suggest that
different fish, even from the same strain, can possess different
ZFERV copy number and integration sites. Moreover, when
Southern hybridizations with an LTR-based probe were
performed, 8–10 bands were seen. Most—but not all—of
these entities were shared by different Tü fish [11]. As with
prior results, this finding might be attributable to variability
in ZFERV copy number and genomic position between
different fish. Another interpretation that must be considered
is that homologous LTRs from other related retroviruses
and/or incomplete ZFERV proviral genomes (having ≥1
LTR, but no env) would yield a similar experimental
outcome.
In spite of these uncertainties, our aCGH data remain
convincing as evidence of somatically acquired ZFERV am-
plifications in D. rerio T-cell cancers. None of our aCGH
probes correspond to LTR sequences, and 5/6 derive from
the retroviral gag, pol, or env genes (Figure 2). Furthermore,
even if repeat elements had been used in hybridizations,
our method of comparing neoplastic to non-malignant DNA
from the same animal is designed to normalize for CNV
discrepancies between different fish. Therefore, we conclude
that zebrafish T-cell malignancies acquire non-germline
ZFERV copies at some point after fertilization, but whether
amplifications precede and contribute to oncogenesis is
unclear.
Because ZFERV transcription occurs in normal zebrafish
T cells [11], we were curious whether normal D. rerio T
lymphocytes might also have ZFERV copy gains. To deter-
mine if retroviral amplifications also occur in nonleukemic
T cells, we investigated ZFERV in normal zebrafish T lym-
phocytes. To emulate our aCGH comparisons, we developed
quantitative PCR (qPCR) assays for two ZFERV genomic
regions. Using DNA from cancers with gains identified by
aCGH, we verified these assays’ ability to detect ZFERV
copy number gains (data not shown). Next, we employed
these qPCRs of amplicons from the pol and env regions
(locations shown in Figure 2) to test genomic DNA from
tailfin tissue and FACS-purified T cells of wild-type (WT)
adult zebrafish. Thymocytes were obtained from WT WIK
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Figure 2: ZFERV Genomic Organization. The ZFERV retrovirus is comprised of two 695 bp long terminal repeats (LTRs), a 517 bp repeat
region (RR) containing 9 direct repeats, and ORFs for 3 proteins: gag, pol, and env [11]. The gag and pol genes share the same reading frame
and are predicted to be translated from one transcript by read-through of a stop codon; env uses a different reading frame and is probably a
distinct transcript [11]. aCGH probe sites are shown beneath the ZFERV genome schematic: probes found on Zv6 chromosomes 7 (∗) and
14 (#) are dispersed throughout ZFERV. One aCGH probe had sequences corresponding to the RR (##), and has multiple binding sites in this
area. The 5 remaining aCGH probes map to ORFs. Amplicons from qPCR and qRT-PCR assays are also depicted (not shown to scale). The
pol and env qPCR products are 168 and 169 bp, respectively; qRT-PCR products are 225 bp for pol and 234 bp for env.
D. rerio carrying an lck::EGFP transgene [12]. Since the
zebrafish lck promoter is T cell specific, T lymphocytes from
this line are GFP+. However, unlike fish with T-ALL or T-
LBL, adult (>6 months of age) WT fish have significantly
fewer T cells (approximately 5 × 104 GFP+ thymocytes/fish;
our unpublished observations). Consequently, we pooled
thymic tissue from several WT fish for FACS purifications.
We then analyzed amplicons from both ZFERV regions to
independently assay copy number differences.
Tailfin DNAs were tested individually or in small groups
to ascertain whether there were appreciable germline CNV
differences in WIK strain fish (Figure 3, lanes 1–6 and 8–
10). As seen in these data, qPCR of pol (Figure 3(a)) and
env (Figure 3(b)) show little deviation between fin DNA
from different WIK fish, implying that CNV was minimal in
these strain-related animals (lanes 7 and 11). Because copy
number was so uniform, this further suggests that ZFERV
amplification does not occur in fin tissue. Thus, we conclude
that ZFERV status in fin tissue likely represents true germline
copy number, and that this level is relatively stable between
individual fish.
In contrast, normal T cells pooled from these same WT
fish showed significant ZFERV gains relative to tailfin DNA
(Figure 3, lanes 12, 13). On average, WIK T cells had 2- to 3-
fold as many ZFERV copies as matched tail DNA (compare
lane 11 to 14). Since germline copy number is unknown, we
cannot deduce the real number of ZFERV copies in these T
cells. Nonetheless, if prior data suggesting 2–4 copies/haploid
genome are accurate [11], these results indicate normal T
cells may average up to 12 copies per haploid genome, or 24
copies/diploid T cell. If correct, this would compute to 16
new ZFERV integrations, on average, in each T cell.
Because we used T lymphocytes pooled from several WIK
fish in these studies, we cannot definitively conclude whether
all animals’ T cells bore evidence of ZFERV amplification. It
is possible that only one or a few fish have ZFERV gains, with
DNA from those fish skewing the average upward. However,
even in one fish, T lymphocytes constitute a nonclonal
population. It is possible—perhaps even likely—that ZFERV
copy number varies on a cell-to-cell basis. ZFERV amplifi-
cations may occur in T cells themselves; alternatively, they
might take place earlier along the hematopoietic stem cell/T
cell progenitor differentiation spectrum. We have not tested
precursor populations, as these are impossible to obtain in
D. rerio owing to the dearth of antibodies to cell surface
receptors. Irrespective of its precise timing, we conclude that
thymocytes acquire additional genomic ZFERV copies at
some point after fertilization, exactly like those detected in
our aCGH analyses of zebrafish T-cell cancers.
Notably, there is precedent proving that ZFERV is active
in zebrafish T cells. This retrovirus was originally discovered
from a thymic cDNA library, after adult D. rerio thymus
had been subtracted against 2-day postfertilization (dpf)
larval fish, which have not yet developed T lymphocytes
[11]. This study identified 43 clones hybridizing to only
adult thymic cDNA. Of these, 21 clones also showed thymus-
specific staining in 7-dpf in situ hybridizations (ISH). After
sequencing, Shen and Steiner recognized that all 21 clones
derived from various segments of the ZFERV genome [11].
So, not only was ZFERV transcribed by both 7-dpf and adult
thymocytes, its expression in these cells was significantly
higher than in other tissues by these two methodologies.
Subsequent ISH experiments in 4-dpf, 5-dpf, and 3-month-
old juvenile fish, as well as Northern blotting of RNA
from adult fish thymocytes, confirmed these findings [11].
Together, these prior studies and our own new findings
demonstrate that ZFERV is highly transcribed by larval and
adult D. rerio thymocytes and that ZFERV amplifications
occur in the genomes of normal and malignant zebrafish T
cells.
To further expand our understanding of these phenom-
ena, we next compared ZFERV amplifications in cancer-
prone thymocytes and neoplastic T cells to WT T cells. For
these experiments, we used our qPCR assays to compare
ZFERV copy number in two other T-cell malignancy pre-
disposed lines, hlk and MYC-ER. Both of these lines are
prone to T-LBL and T-ALL, allowing ZFERV quantification
of their germlines, their “premalignant” T lymphocytes,
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Figure 3: ZFERV amplifications in WT WIK D. rerio T cells. Genomic DNA from 15 WIK lck::EGFP fish was analyzed by qPCR of the
ZFERV pol (a) and env (b) genes. White bars depict results from tail DNA of individual fish (lanes 1–6) or groups of 3 fish (lanes 8–10).
Black bars show calculated means of 6 singly tested tails (lane 7) or all 15 tails (lane 11). “Tails 7–9” sample (lane 8) was arbitrarily assigned
copy number equal to 1, and this DNA was used as the reference standard for all subsequent qPCRs. T cells pooled from 9 or 6 WT fish (gray
bars) had 2- to 3-fold gains in ZFERV. Mean copy number was higher in T cells than tailfin DNA for the 15 fish cohort (lane 11 versus 14).
Zebrafish elf2a (1 copy/haploid genome) qPCR was used to normalize pol and env results (not shown). Water-only template controls lacked
detectable product (not shown). Reactions were performed in triplicate, and error bars show standard deviations (env qPCR of tails 2 and 5
had standard deviations too small to be seen).
and their malignant T cells. All MYC transgenic fish
have hypertrophic thymi, likely reflecting abnormal T-cell
proliferation and physiology. In contrast, hlk fish carry
an unidentified mutation, display normal-appearing thymi,
and the molecular basis for their cancer predisposition is
unknown. T-ALL or T-LBL afflicts roughly 35% of hlk
homozygotes by one year [6], reflecting a requirement for
additional mutations to promote malignant transformation
[8]. By comparison, WT lck::EGFP fish rarely develop T-
cell cancers (<0.1%, our unpublished observations) and
have normal T-cell development and physiology [12]. Thus,
using these samples we could investigate whether normal,
abnormal, and neoplastic T cells all exhibited similar degrees
of ZFERV amplification.
As in earlier experiments, we examined tailfins from
individual fish to ascertain ZFERV germline variability. Tails
from single hlk and MYC-ER fish (Figures 4 and 5, lanes 3–
8) demonstrated consistent copy number between animals.
Moreover, both hlk and MYC-ER tails had ZFERV CNV
similar to the WT WIK line (compare lane 1 to other white
bars in Figures 4 and 5). Based on these results, identical for
both the pol and env regions, we conclude that all 3 lines
have approximately equivalent germline copies of ZFERV.
In pooled premalignant T cells (i.e., thymocytes from hlk
and MYC-ER fish lacking tumors or other non-thymic GFP),
genomic ZFERV was again elevated relative to tailfin DNA
from the same fish (Figures 4 and 5, compare gray bars in
lanes 10-11 to white bars in lanes 3–8). Overall, mean T-cell
ZFERV copy number was roughly 3-fold above germline in
WT, 4-fold higher in hlk, and 5-fold increased in MYC-ER
(compare lane 9 to 12 in both figures). Since WT, hlk, and
MYC-ER thymocytes all showed approximately equivalent
gains, we infer that genomic integration is not appreciably
enhanced in T lymphocytes of either cancer-prone genotype.
Thus, while retroviral amplification is clearly a common
feature of all D. rerio T cells, cancer predisposition probably
does not directly originate from increased susceptibility to
ZFERV integration, as these events evidently transpire in
normal T cells regularly. However, it is plausible that cancer
predisposing mutations and ZFERV copy number gains may
cooperate to promote malignant transformation of T cells,
as amplifications were uniformly present in every T-ALL
sample examined by aCGH.
To investigate how WT and cancer-prone T cells compare
to actual neoplasias in the hlk and MYC-ER lines, we also
analyzed malignancies from these same genetic backgrounds.
We performed pol and env qPCRs on 3 hlk and 5 MYC-ER
fish, each of which had large thymic tumors and/or extensive
GFP+ disease in extra-thymic areas (Figures 4 and 5). Tail
DNA from these 8 fish all had similar germline ZFERV
content to previously tested tailfin samples (compare lanes
13–15 in Figure 4 and lanes 13–17 in Figure 5 to other white
bars in both figures). Like hlk T lymphocytes, hlk cancers had
ZFERV amplification (Figure 4, lanes 16–18). However, gains
were similar in magnitude to those seen in hlk premalignant
T cells (compare lane 12 versus 19). In MYC-ER cancers,
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Figure 4: ZFERV amplifications in hlk zebrafish. DNA from 6 hlk fish with normal phenotype and 3 with GFP+ cancers was tested by qPCR
of pol (a) and env (b). White bars show tail DNA of individual normal (lanes 3–8) or T-ALL+ (lanes 13–15) fish. All were statistically similar
to each other and to WT Tails 7–9 (lane 1). Pooled T cells from hlk fish without T-ALL (gray bars) had ZFERV gains comparable to normal
WIK T cells (lane 2). Mean copy number was higher in hlk T cells than tails (lane 9 versus 12) in the same animals. Diagonally striped bars
show amplifications in neoplastic T cells of 3 hlk fish (lanes 16–18). Mean copy gains were similar in non-malignant and malignant hlk T
cells (lane 12 versus 19). Other details are as described in the legend to Figure 3.
ZFERV gains were also detected (Figure 5, lanes 18–22). As
in hlk, benign and malignant MYC-ER T cells did not show
appreciable copy number differences (compare lane 12 to
23).
We also tested 2 other malignancies by qPCR. In one WT
lck::EGFP fish, we noticed a large GFP+ thymic tumor. In
our experience, the spontaneous occurrence of T-cell cancer
in WT fish is exceedingly rare, so we used this opportunity
to investigate whether ZFERV amplification accompanied
this event. Tail DNA indicated this animal had normal
ZFERV germline content (Figure 6, compare lane 1 versus 9),
and cancerous T cells from this fish showed approximately
5.5-fold higher copy number (lane 10). This degree of
amplification is roughly twice that seen in normal WIK T
cells and more closely resembled typical copies in MYC-ER
T cells and cancers (compare lane 10 to lanes 4, 6, and 8).
However, since this result reflects only one tumor, no general
conclusions can be drawn about retroviral amplification in
the rare cancers of WT fish. Lastly, in one additional hlk
cancer, we found remarkably high ZFERV levels, showing
25- to 30-fold amplification above germline (lanes 11 and
12). This degree of copy number gain is nearly ten times
higher than the other 9 T-ALLs we examined by qPCR, or the
8 tested previously by aCGH. Nonetheless, this infrequent
scenario clearly demonstrates that ZFERV can parasitize the
zebrafish genome in striking fashion, as this cancer likely
harbors as many as 50–100 newly acquired retroviral copies.
Taken together, we conclude that virtually all MYC-
driven, hlk-, srk-, and otg-induced, or even spontaneous
zebrafish T-cell cancers have ZFERV amplifications. How-
ever, since nearly all benign, cancer-prone, and malignant
T cells show similar genomic levels, the absolute amount of
ZFERV amplification does not appear to be an important
oncogenic determinant. This is not surprising, as it is likely
that the site rather than the number of integrations is the
crucial factor. To pursue this premise, one could identify new
loci where ZFERV has integrated into cancer genomes, with
the hypothesis that these might lie near or within proto-
oncogenes or tumor suppressors. We have initiated such
studies, and they are currently in progress. As an adjunct,
we chose to investigate transcription of ZFERV-derived
RNAs. We reasoned that integrations into transcriptionally
permissive genomic sites might be accompanied by increased
ZFERV RNA expression, perhaps signifying “active” proviral
copies. While these insertions might not denote sites where
oncogenes or tumor suppressor reside, it could serve as a
proxy for ZFERV promoter potency in the genome overall.
If so, this predicts that cancers would have higher ZFERV
transcription than normal T cells and perhaps premalignant
T lymphocytes as well.
To conduct these studies, we developed quantitative
Reverse Transcription-Polymerase Chain Reactions (qRT-
PCR) of the ZFERV pol and env genes (amplicon locations
shown in Figure 2). As for qPCR, we used pooled normal
T cells from WT WIK fish as our reference. Recall that
even normal T lymphocytes highly express ZFERV tran-
scripts [11], so these RNAs are already plentiful in the
cells used as our standard. Results for pol and env were
highly reproducible between two pooled T-cell samples from
different groups of WT fish, and this value was arbitrarily
assigned an expression level of 1 (Figure 7, lanes 1 and
2). By comparison, pooled pre-cancerous T cells from hlk
fish exhibited approximately 6-fold and 7-fold enhanced
pol and env transcription, respectively (lane 3, white bar).
Likewise, pooled premalignant T cells from MYC-ER fish also
had higher ZFERV transcripts (lane 9; pol: 9-fold increase,
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Figure 5: ZFERV amplifications in MYC-ER zebrafish. Phenotypically normal (n = 6) or T-ALL+ (n = 5) MYC-ER fish were tested by
qPCR of pol (a) and env (b). White bars display tail DNA from single normal (lanes 3–8) or diseased (lanes 13–17) fish. MYC-ER tails had
similar copy number to each other (compare lanes 3–8 and 13–17) and to WT Tails 7–9 (lane 1). T cells pooled from groups of 3 normal
MYC-ER fish (gray bars) showed ZFERV amplification; higher gains were seen in MYC-ER than WT T cells (lane 2 versus 12; P values 5.86
× 10−4 for pol, 0.15 for env). T cells showed 4- to 5-fold higher ZFERV copy than matched tails (lane 9 versus 12). Diagonally hatched bars
depict amplifications in T-ALL cells from 5 MYC-ER fish (lanes 18–22). Cancer ZFERV levels were well above paired tails (compare lanes
13–17 to 18–22). Slightly lower gains were seen in cancerous than non-malignant MYC-ER T cells (lane 12 versus 23); this reached statistical
confidence for pol, but not env. Other details are as listed in Figure 3’s legend.
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Figure 6: ZFERV amplifications in two other D. rerio T-cell cancers. One WT WIK fish spontaneously developed a GFP+ thymic tumor and
was tested by qPCR of pol (a) and env (b). Average copy numbers of other samples tested previously are shown as black bars. Germline ZFERV
copy number in this fish (lane 9) was similar to the 15 WIK fish already examined (lane 1). This tumor showed 5.5-fold amplification (lane
10, diagonal bar), similar to non-malignant T cells and cancers from WT, hlk, and MYC-ER fish (lanes 4–8). One other hlk T-ALL exhibited
high-level, 25- to 30-fold gains (lane 12), although its germline copy number (lane 11) was comparable to other fish (lanes 1–3).
env: 2.5-fold increase). So, while ZFERV genomic amplifi-
cation did not differ impressively between WT and cancer-
prone T cells (3- to 5-fold; Figure 6), expression of retrovi-
ral transcripts was more pronounced in T cells from both
cancer-prone genotypes.
We also examined T-cell cancers from both lines (n = 10;
4 hlk, 6 MYC-ER). In hlk malignancies, all 4 cancers (lanes
4–7, gray bars) showed increased pol and env compared to
normal T cells. One cancer (hlk T-ALL 4; lane 4) resembled
premalignant hlk T cells in its transcriptional profile. This
same tumor had also been tested by qPCR and showed
comparable ZFERV amplification to non-malignant hlk T
cells (see Figure 4, lanes 12 and 16). So, in this instance, copy
number mirrored ZFERV expression. Three other hlk cancers
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Figure 7: ZFERV gene expression by normal and abnormal D. rerio T cells. Total RNA was tested by qRT-PCR of the ZFERV pol (a) and env
(b) genes. Normal T cell RNA pooled from WIK fish (n = 16 and 18; lanes 1, 2) were used as control, and the “WIK T cells 16–31” sample
was arbitrarily set to an expression value = 1. Premalignant T lymphocytes from hlk (n = 6) and MYC-ER (n = 3) fish had higher expression
than WT fish (white bars; lanes 3, 9), and this higher transcription reached statistical significance. Individual cancers from hlk (n = 4; lanes
4–7) and MYC-ER (n = 6; lanes 10–15) fish are depicted with gray bars. Cancer cells from these fish invariably showed higher pol and env
transcripts than T cells from WT fish, and nearly always had elevated RNA expression relative to normal T cells from these same two lines.
Mean expression of pol and env in malignant T cells (black bars; lanes 8, 16) exceeded both WT and premalignant T cell transcript levels.
Two cancers highlighted by asterisks (hlk T-ALL 4, hlk T-ALL 7; lanes 4, 5) were also tested for genomic copy number by qPCR. The hlk
T-ALL 4 cancer had ZFERV copy number similar to hlk premalignant T cells (see Figure 4), and its pol and env expression also resembled
hlk T cells. Cells from the hlk T-ALL 7 sample had high-level genomic ZFERV gains (see Figure 6), and likewise demonstrated dramatically
increased ZFERV transcription.
(Figure 7, lanes 5–7) had greater pol and env transcription
than hlk premalignant T cells, with at least 2-fold increases
in both transcripts. One of these (hlk T-ALL 7; lane 5) had
markedly higher levels, with 13-fold pol upregulation and
7-fold higher env than non-malignant hlk T cells (lane 3).
The hlk T-ALL 7 sample was also analyzed by qPCR and
exhibited high copy gains (Figure 6, lane 12), providing a
second example that correlated genomic copy number to
ZFERV transcriptional activity. Overall, mean transcription
was 5-fold greater for pol and 3-fold higher for env in hlk
cancers than their pre-cancerous T lymphocytes (compare
lane 3 versus 8), although the hlk T-ALL 7 cancer skews
this result somewhat. That notwithstanding, every hlk cancer
showed ≥4-fold upregulation of both transcripts relative to
WT thymocytes, proving that higher ZFERV expression does
coincide with malignancy.
Similar findings were also obtained in 6 MYC-ER cancers
(lanes 10–15, gray bars). Although transcript levels varied in
individual cancers, mean pol expression was 2-fold increased
and env was 3-fold higher in all six malignancies compared
to MYC-ER premalignant T cells (compare lane 9 versus 16).
Expression of pol and env by the same tumor usually followed
the same trend. However, some cancers did have discordant
transcription of these two genes. Despite these disparities,
MYC-ER cancers averaged 18- and 7-fold higher pol and
env, respectively, than normal T cells from WT fish, further
implicating ZFERV in zebrafish T-cell oncogenesis.
Though ZFERV copy number and transcriptional activ-
ity correlated in the two cancers where we evaluated both
genomic and expression data, variation between pol and
env in the same tumor requires another explanation. Unlike
ZFERV gag-pol, which is thought to be transcribed as a single
RNA, pol and env come from distinct transcripts [11]. Thus,
these genes could be differentially regulated. In addition,
other factors may impact overall ZFERV transcription.
As noted previously, certain integration sites might foster
retroviral activity. In addition, cancers with very high copy
number might be expected to have commensurate RNA
levels, and our limited data support this. Another potential
factor regulating transcription pertains to normal patterns
of ZFERV expression in T lymphocytes. While it is known
that D. rerio T cells normally make ZFERV RNA ([11]
and this work), it is not known if all T-lineage cells do,
or rather if only some T lymphocyte developmental stages
have active ZFERV. Since T-ALL can exhibit differentiation
arrests at multiple maturational stages [13, 14], it is possible
that individual cancers with differing arrest points might
also demonstrate different ZFERV transcription patterns.
Unfortunately, the lack of antibody reagents able to recognize
zebrafish T cell surface markers currently limit testing of this
latter hypothesis.
Despite these limitations, our findings indicate that both
genomic amplification and transcription of ZFERV may im-
pact normal D. rerio T-cell biology and oncogenesis. In
10 Advances in Hematology
particular, our results bolster the notion that new retroviral
integrations could be pathologic on the molecular level. Sta-
bly integrated retroviral elements are common in vertebrate
genomes, with nearly 10% of the human genome comprised
of ERVs or their derivatives [15]. However, most ERVs are
inert due to their accrual of point mutations and partial
deletions. ZFERV is atypical in that its genes apparently
retain unmutated ORFs. Moreover, these genes are robustly
transcribed by D. rerio T cells as verified by ISH, Northern
blotting, and qRT-PCR ([11] and this paper). The abundance
of ZFERV RNA in T lymphocytes is perhaps not surprising,
as ZFERV’s LTR was the most potent promoter among
several transcriptional regulatory sequences assayed in a carp
(Cyprinus carpio) epithelial cell line, including the oft-used
CMV promoter [16].
Rather, ZFERV’s apparent T-cell specificity may be the
more intriguing finding. Shen and Steiner identified putative
binding sites for the lymphoid transcription factors Ikaros
and Tcf3 (E47) in the ZFERV LTR, but also for other
factors (FOS/JUN, C/EBP, STAT, NF-κB, and others) that
are more general activators of transcription [11]. Indeed,
the sequencing of ZFERV-derived transcripts by EST projects
from several other tissue types suggests that non-T-cells may
transcribe ZFERV also [11]. Whether this finding reflects
low-level ZFERV transcription by other cell types, or low-
level T-cell contamination in these tissues, is not clear.
In either case, the atypical persistence of intact ZFERV
ORFs, and their transcriptional activity in zebrafish T cells,
raises the question of whether ZFERV proteins might serve
a functional purpose. Selective pressure would normally
favor mutations disabling a potentially genotoxic retrovirus.
Instead, we hypothesize that ZFERV may in fact serve
some important biologic role, accounting for its paradoxical
maintenance as an active retrovirus in the zebrafish genome.
ZFERV’s apparent absence in the genomes of other Danio
genera [11] implies that its entry into zebrafish is fairly
recent in evolutionary terms, but ZFERV sequences have
been identified from several different strains, suggesting
that its integration is pervasive in the species. It is not
known whether ZFERV is present in all D. rerio, and to
our knowledge, this question has not been investigated. To
date, the closest relative to ZFERV is an exogenous piscine
retrovirus, SSSV. Curiously, this virus is linked to swim
bladder leiomyosarcomas in Atlantic salmon, and like our
results with ZFERV, these tumors show high copy number
proviral SSSV integration [17].
Besides its close relation to SSSV, ZFERV also shares se-
quence conservation and similar genomic structure with
gammaretroviridae of the murine leukemia virus (MLV)
class [11, 17]. MLV-related retroviruses are known to be
oncogenic by insertional mutagenesis [18], and the determi-
nants governing their preferred integration sites have been
the subject of intense scientific scrutiny [19–21]. Although
an obvious ZFERV homologue has not been identified in
humans, other MLV-related sequences have been detected in
human cell lines. However, it appears that these retroviral
sequences may have been acquired by human cells during
xenografting into murine recipients or result from reagent
contamination by murine DNA [22, 23]. In addition, a
long ORF on human chromosome 14 bears high homology
to ZFERV’s env, and upstream sequences contain a short
gag-pol element [24]. So, ZFERV-related retroviruses are
evidently integrated in the human genome as well. Incorpo-
rating all these circumstantial data, it becomes plausible that
ZFERV integrations—like SSSV and MLV—may not only be
oncogenic in zebrafish, but might also have relevance for
human biology in general.
4. Conclusions
Nearly a decade ago, Shen and Steiner discovered a zebrafish
endogenous retrovirus, ZFERV, based on its high transcrip-
tional activity in larval and adult D. rerio thymocytes [11].
Their work suggested that multiple copies of ZFERV existed
in the zebrafish genome, and since that time, the loci where
ZFERV resides still have not been definitively assigned. These
difficulties are probably attributable to the fact that this
multicopy locus may vary in copy number and genomic
positioning in different fish. Amidst this backdrop, we have
found that ZFERV copy number is increased still further
in every D. rerio T-cell malignancy we examined from 4
different genetic lines.
Somewhat surprisingly, our results demonstrate that
ZFERV amplification is not unique to cancerous T cells.
Rather, copy number gains also occur in T lymphocytes
of WT D. rerio, the same cells where ZFERV transcription
was first identified. Moreover, ZFERV copy number appears
to be fairly consistent amongst normal, premalignant, and
malignant T cells (Figure 6, lanes 4–8), although individual
cancers can occasionally show even higher levels of ZFERV
in their genomes. It is possible that individual normal T cells
have similar variability in ZFERV copy number, but this has
not been experimentally addressed.
As seen with genomic amplifications, ZFERV transcrip-
tion occurs within normal, pre-cancerous, and neoplastic T
cells. Our results suggest that expression of ZFERV RNAs
is higher in cancer samples, but we do not recognize a
consistent trend from one cancer to the next. Nonetheless,
these commonalties between normal and malignant T
lymphocytes imply that ZFERV activation and amplification
may be a normal feature of zebrafish T cell biology, with
no pathologic consequence. Still, ZFERV’s abundant tran-
scription, apparently functional ORFs, and ability to undergo
genomic amplification all allude to its oncogenic potential.
Compounded with mutations like hlk, srk, and otg that
confer malignancy predisposition, ZFERV may help promote
T-cell transformation. Given that the closest phylogenetic
relatives of ZFERV are an exogenous piscine retrovirus linked
to sarcomagenesis and MLV-class retroviruses that are leuke-
mogenic via genomic integration, it is tempting to speculate
that ZFERV may contribute to cellular immortalization by
similar mechanisms.
Certainly, ZFERV integrations in crucial genomic sites
could have transformative properties. For example, integra-
tion within a tumor suppressor gene might render it unable
to generate its normal protein product, thereby ablating
function. Conversely, integrations into the promoter or
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enhancer regions of proto-oncogenes might augment their
transcription. Since ZFERV appears to be specifically and
highly expressed by thymocytes, this scenario could be
analogous to the translocation of proto-oncogenes into the
T-cell receptor loci, which are well described in T-ALL
[25, 26]. However, proof of this hypothesis will require
identification of somatically acquired ZFERV integrations at
these genomic sites. At this point, the possibility that ZFERV
amplifications may contribute to T-cell oncogenesis remains
an open question that will require further investigation to
resolve decisively.
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